The latest price target for Keros Therapeutics (NASDAQ:KROS) was reported by Wells Fargo on March 5, 2026. The analyst firm set a price target for $20.00 expecting KROS to rise to within 12 months (a possible 70.50% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ:KROS) was provided by Wells Fargo, and Keros Therapeutics maintained their overweight rating.

There is no last upgrade for Keros Therapeutics

The last downgrade for Keros Therapeutics Inc happened on June 10, 2025 when B of A Securities changed their price target from $32 to $18 for Keros Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on March 5, 2026 so you should expect the next rating to be made available sometime around March 5, 2027.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a maintained with a price target of $23.00 to $20.00. The current price Keros Therapeutics (KROS) is trading at is $11.73, which is out of the analyst’s predicted range.